CARDIO DIAGNOSTICS HOLDINGS INC (CDIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.68+1.52%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CDIO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
THE CARE CONTINUUM Risk Assessment Risk Management Early Diagnosis Medical Management & Lifestyle Modifications Monitor Effectiveness Ongoing Evaluation 4 To our knowledge, we have developed the firs…
Stated in a supplied disclosure. Management reported: “Market opportunity reflects potential, not current or near - term revenue.” “Price for te st can vary for patients and organizations.” Revenue was $0.005 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Market opportunity reflects potential, not current or near - term revenue.
Stated in a supplied disclosure. Management reported: “Market opportunity reflects potential, not current or near - term revenue.” “Price for te st can vary for patients and organizations.” Operating income was $-1.498 million in 2026-Q2.
Market opportunity reflects potential, not current or near - term revenue.
Stated in a supplied disclosure. Management reported: “Market opportunity reflects potential, not current or near - term revenue.” “Price for te st can vary for patients and organizations.”
Market opportunity reflects potential, not current or near - term revenue.
Stated in a supplied disclosure. Management reported: “Market opportunity reflects potential, not current or near - term revenue.” “Price for te st can vary for patients and organizations.”
Over the trailing year it converted 0.65x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
3 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.